BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 15364449)

  • 21. Enhancement of suicidal DNA vaccine potency by delaying suicidal DNA-induced cell death.
    Kim TW; Hung CF; Juang J; He L; Hardwick JM; Wu TC
    Gene Ther; 2004 Feb; 11(3):336-42. PubMed ID: 14737094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant effect of dendritic cells transduced with recombinant vaccinia virus expressing HPV16-E7 is inhibited by co-expression of IL12.
    Mackova J; Kutinova L; Hainz P; Krystofova J; Sroller V; Otahal P; Gabriel P; Nemeckova S
    Int J Oncol; 2004 Jun; 24(6):1581-8. PubMed ID: 15138603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins.
    Davidson EJ; Boswell CM; Sehr P; Pawlita M; Tomlinson AE; McVey RJ; Dobson J; Roberts JS; Hickling J; Kitchener HC; Stern PL
    Cancer Res; 2003 Sep; 63(18):6032-41. PubMed ID: 14522932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice.
    Eiben GL; Velders MP; Schreiber H; Cassetti MC; Pullen JK; Smith LR; Kast WM
    Cancer Res; 2002 Oct; 62(20):5792-9. PubMed ID: 12384540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fusion of a tumour-associated antigen to HIV-1 Tat improves protein-based immunotherapy of cancer.
    Giannouli C; Brulet JM; Gesché F; Rappaport J; Burny A; Leo O; Hallez S
    Anticancer Res; 2003; 23(4):3523-31. PubMed ID: 12926102
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus.
    Kass E; Schlom J; Thompson J; Guadagni F; Graziano P; Greiner JW
    Cancer Res; 1999 Feb; 59(3):676-83. PubMed ID: 9973217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Viral recombinant vaccines to the E6 and E7 antigens of HPV-16.
    He Z; Wlazlo AP; Kowalczyk DW; Cheng J; Xiang ZQ; Giles-Davis W; Ertl HC
    Virology; 2000 Apr; 270(1):146-61. PubMed ID: 10772987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Non-replicating recombinant vaccinia virus expressing HPV16 E6 and E7 proteins elicits anti-tumor immunity in mice].
    Luo WF; Han LQ; Ren J; Tian HW; Lu ZH; Zhao L; Gu SY; Ruan L
    Zhonghua Zhong Liu Za Zhi; 2003 Jul; 25(4):335-9. PubMed ID: 12921560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6.
    Peng S; Ji H; Trimble C; He L; Tsai YC; Yeatermeyer J; Boyd DA; Hung CF; Wu TC
    J Virol; 2004 Aug; 78(16):8468-76. PubMed ID: 15280455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice.
    Peng S; Trimble C; He L; Tsai YC; Lin CT; Boyd DA; Pardoll D; Hung CF; Wu TC
    Gene Ther; 2006 Jan; 13(1):67-77. PubMed ID: 16107858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pre-clinical immunogenicity and anti-tumour efficacy of a deleted recombinant human papillomavirus type 16 E7 protein.
    Hallez S; Brulet JM; Vandooren C; Maudoux F; Thomas S; Heinderickx M; Bollen A; Wattiez R; Jacquet A
    Anticancer Res; 2004; 24(4):2265-75. PubMed ID: 15330171
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Experimental therapy of HPV16 induced tumors with IL12 expressed by recombinant vaccinia virus in mice.
    Nemeckova S; Sroller V; Hainz P; Krystofova J; Smahel M; Kutinova L
    Int J Mol Med; 2003 Nov; 12(5):789-96. PubMed ID: 14533011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors.
    Matsumoto K; Leggatt GR; Zhong J; Liu X; de Kluyver RL; Peters T; Fernando GJ; Liem A; Lambert PF; Frazer IH
    J Natl Cancer Inst; 2004 Nov; 96(21):1611-9. PubMed ID: 15523090
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.
    Hodge JW; Poole DJ; Aarts WM; Gómez Yafal A; Gritz L; Schlom J
    Cancer Res; 2003 Nov; 63(22):7942-9. PubMed ID: 14633725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia.
    Baldwin PJ; van der Burg SH; Boswell CM; Offringa R; Hickling JK; Dobson J; Roberts JS; Latimer JA; Moseley RP; Coleman N; Stanley MA; Sterling JC
    Clin Cancer Res; 2003 Nov; 9(14):5205-13. PubMed ID: 14614000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Experimental study of the immuno-protective activity of recombinant vaccinia virus expressing HPV58 E7].
    Luo LQ; Li J; Liu X; Zhang YH
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Feb; 25(1):43-6. PubMed ID: 12905606
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein.
    Préville X; Ladant D; Timmerman B; Leclerc C
    Cancer Res; 2005 Jan; 65(2):641-9. PubMed ID: 15695409
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8-positive memory T cells and protective immunity.
    Kim TW; Hung CF; Kim JW; Juang J; Chen PJ; He L; Boyd DA; Wu TC
    Hum Gene Ther; 2004 Feb; 15(2):167-77. PubMed ID: 14975189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Immunogenicity of mutant and wild HPV16 DNA vaccines].
    Zuo YG; Wang JB; Jin HZ; Yue-hua L
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Oct; 26(5):554-7. PubMed ID: 15562771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.